Opinion & analysis | Page 2 of 20 | Report Store

House Committee Hearing Shows How Talc/Asbestos Concerns Could Be Impetus For Cosmetics Reform

During the first hearing of the Subcommittee on Economic and Consumer Policy, part of the House Committee on Oversight and Reform, US lawmakers focused on the issue of the safety of talc and asbestos in personal care items.

March 12, 2019

Find out more

Pharma Intelligence Report Store Article Collection Innovation, Data and Machine Learning Report 2

$500.00

OTC drug firms should offer more digital tools that guide consumers in product purchases, says a health care marketing executive. The American Pharmacists Association suggests firms also strengthen outreach with pharmacists.

March 16, 2017

Find out more

Patient-Specific Drive Takes Ortho Group Corin Into TKR Robotics With Omni Purchase

$131.00

Knee and hip replacement company Corin Group PLC has acquired Omni Orthopedics Inc. The acquisition of Omni, which specializes in robotic-assisted total knee replacement, marks another major step in the company’s expansion in the orthopedic market.

March 6, 2019

Find out more

A Hangover Is A Disease, German Court Rules

$131.00

Alcohol-related hangovers are genuine illnesses according to a recent ruling by a high-level German court. HBW looks at the case against a German wellness manufacturer for health claims made for its “anti-hangover” supplements and how deeming hangover’s a disease affects the outcome of the case.

September 2, 2019

Find out more

Peter Stein Takes Short Path To Director Of US FDA Drug Office

$131.00

After only a short stint at the US FDA as Deputy Director of the Office of New Drugs, industry veteran Peter Stein was appointed to his permanent post as Director of the OND in December of 2018, filling a role that sat vacant for nearly two years.

December 9, 2018

Find out more

Pfizer Price Increases Underscore Rebate Problem, HHS’ Hargan Says

$131.00

At December’s FDA/CMS Summit in Washington, Health and Human Services Secretary Eric Hargan used Pfizer’s recent price hike of 41 of its products as evidence that higher drug costs are a direct result of the rebate system, a viewpoint touted by the Trump administration in their quest to lower drug prices.

December 12, 2018

Find out more

Big Pharma CEOs Get Ready To Testify: Preparing For A No-Win Situation

$131.00

Leading pharmaceutical executives called to testify before a Senate Finance Committee hearing on drug prices were likely the first of many to be summoned. It’s a no-win situation, but preparation can help. Find out why changing the subject can be a smart tactic. Discover how some senators may try to lure execs into inadvertently lying–and learn how to avoid it.

May 13, 2019

Find out more

Top 10 Drugs: Biologic Blockbusters And The Biosimilar Threat

$131.00

Pharma companies faced a “patent cliff” a decade ago with generic competition threatening to slash sales of certain blockbusters. The new threat is biosimilars. Scrip shows how some mature cancer and autoimmune biologics are still the major drivers of revenues, and how biosimilars are gaining on them.

August 9, 2019

Find out more

Transforming Pharmaceutical R&D with Data

$2,995.00

Ongoing pressures on drug pricing and reimbursement mean that current research and development (R&D) economics are unsustainable. The process of discovering and developing a drug has not fundamentally changed for decades, and on average it still costs $2.6bn and takes over 10 years. Fortunately, tools are emerging to help improve R&D success rates. Most are built on better use of more kinds of data, including using artificial intelligence (AI) to process massive quantities of information that humans cannot manage. Some of these new tools promise cost and time savings of between 20–50%

May 2, 2017

Find out more

Pharma Intelligence Report Store Article Collection Innovation, Data and Machine Learning Report 1

$500.00

Real-world evidence promises to solve many problems inherent in getting a drug to patients at a good price. It could slash development costs and help make the reimbursement case to payers. But there are challenges for companies that want to exploit real-world evidence to get their drug to patients in Europe.

November 22, 2016

Find out more

Anti-Aging Cosmetics Or Unlawfully Marketed Drugs? Two Federal Court Cases To Watch

$131.00

Skin-firming and anti-wrinkle claims on products marketed as cosmetics are being tested in California federal course. The results will have considerable implications on the health, beauty and wellness industry. HBW looks at similarities and differences of the two cases.

September 2, 2019

Find out more

Repositioning Market Access: A Function Fit For Purpose In A New Era Of Costly Cures

$200.00

Explore the findings of an October 2018 panel discussion of market analysts and market access specialists as they discuss the question: As new cures and treatments for patients develop, how does the conversation shift from delivering market access to products to focusing on patient access to progress?

November 28, 2018

Find out more

EU Beats Predicted Timelines And Appoints First UK Notified Body Against MDR

$131.00

Months ahead of schedule, the EU Medical Devices Regulation has succeeded in designating its first notified body. BSI UK achieved designated status much sooner than anticipated, but does that mean the road ahead for other designations will be as smooth?

January 22, 2019

Find out more

Herbalife Shakes Up Executive Suite Due To CEO’s Earlier Statements On Expenses

$131.00

Herbalife CEO Richard Goudis stepped down from the top spot at the company following the discovery of inappropriate comments he had made prior to becoming CEO. Find out more about the Herbalife shakeup and what it means for the company.

January 8, 2019

Find out more

Colgate/Tom’s Of Maine Pays Back Unilever For ‘Naturally Dry’ Loss

$131.00

It’s payback time for Unilever, as the maker of Schmidt’s deodorants must re-label its products, removing reference to certain wetness-absorption claims. In 2016, Unilever was responsible for making close competitor Colgate’s Tom’s of Maine remove similar claims to their deodorant products at a self-regulatory forum.

June 7, 2018

Find out more